NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Stock Information for NeuroSense Therapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroSense Therapeutics Ltd.

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense to Host Investor Webinar on December 8, 2025
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Provides Business Update and Progress for the First Half of 2025
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.